Vitamin D suppresses cellular pathways of diabetes complication in liver | ||
| Iranian Journal of Basic Medical Sciences | ||
| مقاله 15، دوره 22، شماره 6، شهریور 2019، صفحه 690-694 اصل مقاله (530.41 K) | ||
| نوع مقاله: Original Article | ||
| شناسه دیجیتال (DOI): 10.22038/ijbms.2019.36054.8584 | ||
| نویسندگان | ||
| Hoda Derakhshanian1، 2؛ Mahmoud Djalali3؛ Mohammad Hassan Javanbakht3؛ Ehsan Alvandi3؛ Mohhamd Reza Eshraghian4؛ Abbas Mirshafiey5؛ Hoda Nadimi3؛ Samane Jahanabadi6؛ Mahnaz Zarei3؛ Abolghassem Djazayery* 7 | ||
| 1Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran | ||
| 2Department of Biochemistry, Genetics and Nutrition, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran | ||
| 3Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran | ||
| 4Department of Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran | ||
| 5Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran | ||
| 6Department of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 7Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran | ||
| چکیده | ||
| Objective(s): The aim of this study was to investigate the effect of vitamin D on glucose metabolism, as well as the expression of five key genes involved in the development of diabetes complications in liver tissue of diabetic rats. Materials and Methods: Twenty-four male Sprague–Dawley rats were randomly divided into three groups (8 rats in each group). The first group served as control and the other two groups received an intraperitoneal injection of 45 mg/kg streptozotocin to develop diabetes. Groups were treated for four weeks either with placebo or vitamin D (two injections of 20000 IU/kg). Thereafter, serum levels of glucose, insulin and HbA1c were assessed. Liver tissue was examined for the level of advanced glycation end products (AGEs) and the gene expression of AGE cellular receptor (AGER), glyoxalase-1 (GLO-1), aldose reductase (AR), O-linked N-acetylglucosamine transferase (OGT) and glutamine/ fructose-6-phosphate aminotransferase (GFAT). Results: Vitamin D injection resulted in a significant increase in plasma level of 25-hydroxycholecalciferol, which could improve hyperglycemia about 11% compared to placebo-receiving diabetic rats (P=0.005). Insulin level increased as a result of vitamin D treatment compared to control (3.31±0.65 vs. 2.15±0.79; P= 0.01). Serum HbA1c and liver AGE concentrations had a slight but insignificant reduction following vitamin D intake. Moreover, a significant decline was observed in gene expression of AGER and OGT in liver tissue (P=0.04 and PConclusion: Vitamin D might contribute in ameliorating diabetes complications not only by improving blood glucose and insulin levels, but also by suppressing AGER and OGT gene expression in the liver. | ||
| کلیدواژهها | ||
| Advanced glycation end products؛ Cholecalciferol؛ Diabetes complications؛ Hexosamine pathway؛ Vitamin D | ||
| مراجع | ||
|
1. Ogurtsova K, da Rocha Fernandes J, Huang Y, Linnenkamp U, Guariguata L, Cho N, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128:40-50. 2. Herman WH. The Global burden of diabetes: An overview. Diabetes mellitus in developing countries and underserved communities: Springer 2017. p. 1-5. 3. Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes—part I: pathways of vascular disease in diabetes. Vascul Pharmacol 2011; 54:68-74. 4. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013; 93:137-188. 5. Group DPPR. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention. Diabetes Care 2012; 35:723-730. 6. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2013; 36:3821-3842. 7. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014; 383:1999-2007. 8. Hyppönen E, Läärä E, Reunanen A, Järvelin M-R, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001; 358:1500-1503. 9. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92:2017-2029. 10. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, et al. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 2011; 34:1400-1402. 11. Shehab D, Al‐Jarallah K, Mojiminiyi O, Al Mohamedy H, Abdella N. Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes? Diabet Med 2012; 29:43-49. 12. Diaz VA, Mainous AG, Carek PJ, Wessell AM, Everett CJ. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 2009; 22:521-527. 13. Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals: Canadian Council on Animal Care Ottawa; 1993. 14. Husemoen LLN, Thuesen BH, Fenger M, Jørgensen T, Glümer C, Svensson J, et al. Serum 25 (OH) D and type 2 diabetes association in a general population. Diabetes Care 2012; 35:1695-1700. 15. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93:512-517. 16. Park S, Kim DS, Kang S. Vitamin D deficiency impairs glucose-stimulated insulin secretion and increases insulin resistance by reducing PPAR-γ expression in nonobese Type 2 diabetic rats. J Nutr Biochem 2016; 27:257-265. 17. Jayanarayanan S, Anju TR, Smijin S, Paulose CS. Vitamin D 3 supplementation increases insulin level by regulating altered IP3 and AMPA receptor expression in the pancreatic islets of streptozotocin-induced diabetic rat. J Nutr Biochem 2015; 26:1041-1049. 18. Yang Z, Liu F, Qu H, Wang H, Xiao X, Deng H. 1, 25 (OH) 2 D 3 protects β cell against high glucose-induced apoptosis through mTOR suppressing. Mol Cell Endocrinol 2015; 414:111-119. 19. Manna P, Jain SK. Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-γ-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes. J Biol Chem 2012; 287:42324-42332. 20. Enciso PL, Wang L, Kawahara Y, Sakamoto S, Shimada S, Takeichi Y, et al. Dietary vitamin D 3 improves postprandial hyperglycemia in aged mice. Biochem Biophys Res Commun 2015; 461:165-171. 21. Beisswenger PJ, Howell SK, Russell GB, Miller ME, Rich SS, Mauer M. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 2013; 36:3234-3239. 22. Sveen KA, Karimé B, Jørum E, Mellgren SI, Fagerland MW, Monnier VM, et al. Small-and large-fiber neuropathy after 40 years of type 1 diabetes. Diabetes Care 2013; 36:3712-3717. 23. Choudhuri S, Dutta D, Sen A, Chowdhury IH, Mitra B, Mondal LK, et al. Role of N–epsilon-carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus. Mol Vis 2013;19:100-13. 24. Ramasamy R, Vannucci SJ, Du Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15:16-28. 25. Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T, et al. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 2011; 286:1374-1380. 26. Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N ɛ-carboxymethyl lysine. J Diabetes Complications 2010; 24:424-432. 27. Hashimoto Y, Yamagishi SI, Mizukami H, Yabe‐Nishimura C, Lim SW, Kwon HM, et al. Polyol pathway and diabetic nephropathy revisited: early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase. J Diabetes Investig 2011; 2:111-122. 28. Akimoto Y, Miura Y, Toda T, Wolfert MA, Wells L, Boons G-J, et al. Morphological changes in diabetic kidney are associated with increased O-GlcNAcylation of cytoskeletal proteins including α-actinin 4. Clin Proteomics 2011; 8:15. 29. Park SY, Ryu J, Lee W. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Exp Mol Med 2005; 37:220-229. 30. Inbathamizh L, Padmini E. In silico studies on the inhibitory effects of calcitriol and 5, 5’-dithiobis-2-nitrobenzoic acid on human glucosaminyl N-acetyl transferase 1 activity. Asian J Exp Biol Sci 2012; 3:14-21. | ||
|
آمار تعداد مشاهده مقاله: 1,212 تعداد دریافت فایل اصل مقاله: 704 |
||